Literature DB >> 27803826

A Corticobasal Syndrome Variant of Familial Creutzfeldt-Jakob Disease with Stroke-Like Onset.

Ján Necpál1, Martin Stelzer2, Silvia Koščová2, Michal Patarák3.   

Abstract

Creutzfeldt-Jakob disease (CJD) is an untreatable rare human prion disease characterized by rapidly progressive dementia along with various neurological features, including myoclonus and sometimes other movement disorders. The clinical course is typically insidious and rapid, leading to an early death. In general, the most common form is sporadic CJD; however, Slovakia is typical for a high percentage of genetic cases. We present an unusual case report of a 65-year-old man with a sudden, stroke-like onset of motor aphasia with right-sided levodopa unresponsive parkinsonism, alien hand, and other characteristic features of corticobasal syndrome (CBS), with rapid deterioration and death on the 32nd day of the disease. Various neurodegenerative disorders are manifested with CBS as a clinical phenotype, including corticobasal degeneration (CBD), progressive supranuclear palsy, Alzheimer's disease, and CJD. In our patient, mutation E200K and M129M polymorphism of the PRNP gene and typical immunohistochemical findings pointed to a diagnosis of CJD. The patient's mother died of CJD many years ago. Several CBS-CJD cases were described, but the atypical stroke-like onset of CBS-CJD, an extremely rare presentation of CJD, makes our case unique worldwide.

Entities:  

Year:  2016        PMID: 27803826      PMCID: PMC5075606          DOI: 10.1155/2016/4167391

Source DB:  PubMed          Journal:  Case Rep Neurol Med        ISSN: 2090-6676


1. Introduction

Creutzfeldt-Jakob disease (CJD) is a rare human prion disease with annual incidence of 1–1.5/million inhabitants, characterized by rapidly progressive dementia, myoclonus, ataxia, visual symptoms, pyramidal and extrapyramidal disturbance, akinetic mutism, and early death [1]. Although the majority of cases are sporadic, genetic forms with CJD-specific mutations also occur. Slovakia is characterized by an unusually high percentage (65–75%) of genetic cases, with mutation E200K of the prion protein gene being the most frequent [2]. Apart from myoclonus, the disease rarely presents with other movement disorders, such as chorea, tremor, dystonia, and parkinsonism, including a progressive supranuclear palsy-like and corticobasal syndrome phenotype [3].

2. Case Presentation

We present a 65-year-old man with a history of hypertension, coronary artery disease, and diabetes admitted to the hospital due to the sudden onset of nonfluent aphasia as a sign of possible stroke. The brain CT with angiography, carotid angiogram, EKG, and echocardiogram were all unremarkable. Logopaedic and psychological assessment revealed motor aphasia, bradylalia, marked response latency, apraxia, acalculia, and alexia with agraphia. The Standardized Mini-Mental State Examination score was 14/30. An EEG on the 6th and 13th day after onset was normal. Over the next few days, the patient developed a shuffling and apractic gait, levodopa unresponsive predominantly right-sided hemiparkinsonism with slight action dystonia of the right hand, upgoing toes, ideomotoric apraxia with forced grasping, mirror movements, alien hand, and positive applause sign—typical features of corticobasal syndrome (CBS). He would sometimes hold his right upper limb for several minutes in an odd-looking posture with extension, levitation, and grasping (probably a manifestation of alien hand syndrome). There were no speech, motor, or cognition problems before the clinical onset of disease. Some members of the patient's family had died of some rapidly progressive neurological disorder, and his mother had definite CJD. Routine biochemistry, ANA and ANCA antibodies, thyroglobulin and thyroid peroxidase antibodies, tests for HIV and syphilis, virology, and onconeural and autoimmune encephalitis antibodies were all negative. There was mild hyperproteinorhachia (0,63 g/L) and increased total tau protein but negative 14-3-3 protein in the cerebrospinal fluid. The EEG taken on the 23rd day displayed marked diffuse slowing with pseudoperiodic generalized triphasic slow wave pattern (Figure 1(a)). Brain MRI performed on the 23rd day revealed slight symmetrical frontoparietal atrophy and high signal in both caudate nuclei and the bilateral frontal and left insular cortex on diffuse-weighted images (DWI) sequence, with no signs of CBS (Figure 1(b)). There were no clear cortical T2 changes. FLAIR sequence was unfortunately not performed. Diagnosis of probable CJD was then made. The disease rapidly progressed into akinetic mutism, with generalized hypertonia and finally death on the 32nd day of the disease. Mutation E200K and M129M polymorphism of the PRNP gene were identified. An autopsy revealed macroscopically a mild diffuse atrophy of the frontal, paracentral, and cerebellar cortex (Figure 1(c)). The typical histopathological triad of spongiosis, neuronal loss, and astrogliosis, as well as immunohistochemically detected pathological prion protein, confirmed the diagnosis of definite CJD (Figure 1(d)).
Figure 1

Antemortem and postmortem findings in an index case. (a) An EEG with pseudoperiodic generalized triphasic slow waves on the 23rd day of the disease. (b) Axial brain DWI shows hyperintense areas in bilateral caudate nuclei, bilateral frontal, and left insular cortex. (c) Macroscopic view of the left frontal lobe atrophy. (d) Immunohistochemical confirmation of prion protein with 6H4 monoclonal antibodies (granular layer of the cerebellar cortex, 400x zoom).

3. Discussion

To date, 39 cases worldwide with the CBS presentation of CJD (CBS-CJD) have been published [4]. Lee et al. reported the clinical characteristics of 20 such autopsy cases with extremely low annual incidence of this condition (0.014/million cases). Mean age at onset was 66 years. They presented with limb apraxia, alien hand phenomenon, dysphasia, cortical sensory loss, myoclonus, dystonia, rigidity, and pyramidal disturbance—classic CBS signs. The only criterion clinically distinguishable between pathologically confirmed CBD with CBS and CBS-CJD was the rapidity of disease progression. Median time from disease onset to death was 68 months in CBD and only 5 months in CBS-CJD [5]. Typical MRI changes, periodic sharp waves on the EEG, and 14-3-3 protein positivity may be helpful for diagnosis (however, they are not specific and may be absent) and along with dementia are otherwise cardinal features of CJD [4, 5]. The presence of true dementia in our patient remains questionable, because cognitive testing was probably influenced by aphasia and apathy. The duration of the illness from onset to death was only 32 days. The clinical course itself was very similar to the reported case of a 73-year-old woman with acute CBS-CJD of four weeks' duration [6], except for being familial in our patient. There is only one reported case of CBS-CJD in the context to familial CJD with the mutation M232R [7]. An extraordinary sudden stroke-like onset of the disease contrasting to more typical gradual onset of CJD, a CBD-look-alike presentation, and finally the familial occurrence of CJD all appeared in one person; therefore, we consider this case as unique and worth reporting. It should serve as a clue for clinicians to keep in mind that rapidly progressive atypical parkinsonian syndromes may masquerade as CJD, and genetic testing for CJD-specific mutations may significantly contribute to differential diagnosis of neurodegenerative disorders.
  6 in total

1.  Presentation of Creutzfeldt-Jakob disease as acute corticobasal degeneration syndrome.

Authors:  Galit Kleiner-Fisman; Catherine Bergeron; Anthony E Lang
Journal:  Mov Disord       Date:  2004-08       Impact factor: 10.338

Review 2.  Movement disorders and Creutzfeldt-Jakob disease: a review.

Authors:  David Maltête; Lucie Guyant-Maréchal; Bruno Mihout; Didier Hannequin
Journal:  Parkinsonism Relat Disord       Date:  2005-12-20       Impact factor: 4.891

3.  Familial Creutzfeldt-Jakob disease with M232R mutation presented with corticobasal syndrome.

Authors:  Jung Geol Lim; Eungseok Oh; Sangmin Park; Yong-Sun Kim; Aeyoung Lee
Journal:  Neurol Sci       Date:  2014-12-17       Impact factor: 3.307

4.  Corticobasal syndrome-like variant of Creutzfeldt-Jakob disease: clinical description of two cases.

Authors:  Valentina Arnao; Massimo Gangitano; Fabio Giacalone; Marianna Riolo; Giovanni Savettieri; Paolo Aridon
Journal:  Neurol Sci       Date:  2014-12-17       Impact factor: 3.307

5.  Characterising the uncommon corticobasal syndrome presentation of sporadic Creutzfeldt-Jakob disease.

Authors:  Will Lee; Marion Simpson; Helen Ling; Catriona McLean; Steven Collins; David R Williams
Journal:  Parkinsonism Relat Disord       Date:  2012-09-01       Impact factor: 4.891

6.  Creutzfeldt-Jakob disease with E200K mutation in Slovakia: characterization and development.

Authors:  E Mitrová; G Belay
Journal:  Acta Virol       Date:  2002       Impact factor: 1.162

  6 in total
  4 in total

Review 1.  Unravelling Genetic Factors Underlying Corticobasal Syndrome: A Systematic Review.

Authors:  Federica Arienti; Giulia Lazzeri; Maria Vizziello; Edoardo Monfrini; Nereo Bresolin; Maria Cristina Saetti; Marina Picillo; Giulia Franco; Alessio Di Fonzo
Journal:  Cells       Date:  2021-01-15       Impact factor: 6.600

Review 2.  Creutzfeldt-Jakob and Vascular Brain Diseases: Their Overlap and Relationships.

Authors:  Yacov Balash; Amos D Korczyn; Nadejda Khmelev; Anda Eilam; Meital Adi; Ronit Gilad
Journal:  Front Neurol       Date:  2021-02-25       Impact factor: 4.003

Review 3.  Neuropathology and emerging biomarkers in corticobasal syndrome.

Authors:  Shunsuke Koga; Keith A Josephs; Ikuko Aiba; Mari Yoshida; Dennis W Dickson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2022-06-13       Impact factor: 13.654

4.  High Incidence of Sporadic Creutzfeldt-Jakob Disease in Slovenia in 2015: A Case Series.

Authors:  Tomaž Rus; Bogdan Lorber; Maja Trošt; Srečko Dobrecovič; Nuška Čakš Jager; Mara Popović; Milica G Kramberger
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2018-02-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.